Parkinson's disease (PD) is a neurodegenerative disease characterized by a progressive degeneration of dopaminergic neurons in the substantia nigra pars compact (SNpc), with consequent depletion of dopamine in the striatum, which gives rise to the characteristic motor symptoms of PD. Although its etiology is unknown, several studies have suggested that oxidative stress plays a critical function in the pathophysiology of PD, and antioxidant agents could be helpful to slown down the dopaminergic neurodegeneration. Carvacrol (CA) is a phenolic monoterpene found in essential oils of many aromatic plants that presents antioxidant and neuroprotective effects. This study aimed to assess the effect of CA in a reserpine (RES)-induced rat model of PD. Male Wistar rats received 15 s.c. injections of 0.1 mg/kg RES or vehicle, every other day, concomitantly to daily i.p. injections of CA (12.5 or 25 mg/kg) or vehicle. Across the treatment, the animals were submitted to behavioral evaluation in the catalepsy test (performed daily), open field test (7th day) and assessment of vacuous chewing movements (12th, 20th and 30th days). Upon completion of behavioral tests, rats were perfused and their brains underwent tyrosine hydroxylase (TH) immunohistochemical analysis. Our results showed that CA (12.5 e 25 mg/kg) prevented the increase in catalepsy behavior and number of vacuous chewing movements, but failed to revert the decreased open-field locomotor activity induced by RES. In addition, CA in both doses prevented the decrease in TH immunostaining induced by RES in the SNpc and dorsal striatum. Taken together, our results suggest that CA shows a protective effect in a rat model of PD, preventing motor and neurochemical impairments induced by RES. Thus, the use of CA as a promising new strategy for the prevention and/or treatment of PD may be considered.
Introduction
Parkinson's disease (PD) is a progressive and age-related neurodegenerative disease and is the second most common neurodegenerative disorder in humans (Lau and Breteler, 2006; Pringsheim et al., 2014) . Although multiple factors are associated with the etiology and pathogenesis of PD, its cause is still unknown. The main pathological hallmark of PD is a progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), with resulting dopaminergic deafferentation in the striatum. This outcome gives rise to cardinal motor symptoms, such as bradykinesia, muscular rigidity, resting tremor and postural instability (Wu et al., 2012; Miller and O'Callaghan, 2015) .
None of the current treatments is able to stop or even slow down the neurodegeneration in PD. Therefore, only symptomatic treatment is available for PD patients (Dexter and Jenner, 2013; Rizek et al., 2016) . Dopamine replacement therapy employing levodopa (L-dopa) remains the primary mode for treatment of motor symptoms of PD. However, the effectiveness of L-dopa therapy declines over time, and motor complications, such as motor fluctuations and dyskinesia, have been associated with long-term L-dopa therapy (Olanow, 2015; Dexter and Jenner, 2013) . Therefore, several studies have focused on identifying new drugs able to improve the motor symptoms and to modify the course of PD.
In the last years, animal models of PD induced by neurotoxins, including reserpine (RES), have been considered a helpful tool to investigate the mechanisms underlying the physiopathology of PD, as well to do screening of new drugs or interventions with neuroprotective effects (Fernandes et al., 2012; Santos et al., 2013; Sarmento Silva et al., 2015; Peres et al., 2016; Campêlo et al., 2017) . Several studies have indicated that a range of pure compounds derived from herbal medicines are effective on in vivo and in vitro PD models via modulation of multiple targets involved in the pathogenesis of PD (Song et al., 2012; Li et al., 2013; Shahpiri et al., 2016) .
Carvacrol (CA) is a phenolic monoterpene found in the essential oils of the Lamiaceae family including Origanum, Thymus, Satureja and Corydothymus. CA is the major constituent of the essential oils of Origanum species (Baser, 2008) . It is considered safe for consumption and is approved by the Food and Drug Administration as a food additive (De Vincenzi et al., 2004) . Studies have shown different pharmacological activities of CA on the central nervous system (CNS), including anxiolytic-like (Melo et al., 2010) , antinociceptive (Melo et al., 2012; Guimarães et al., 2012) , antidepressant (Melo et al., 2011 ), anticonvulsant (Quintans-júnior et al., 2010 , antioxidant, anti-inflammatory and neuroprotective (Yu et al., 2012; Baluchnejadmojarad et al., 2014; Deng et al., 2013; Li et al., 2016; Peters et al., 2012) effects.
It has been reported that inflammation and oxidative stress are involved in the pathogenesis of dopaminergic neurodegeneration in PD (Uttara et al., 2009; Janda et al., 2012; Rocha et al., 2015; Le et al., 2016) . Thus, anti-inflammatory and antioxidant agents could be alternative strategies for prevention or treatment of PD (Hwang, 2013; Wang et al., 2015) . In this respect, previous studies have shown that CA has anti-inflammatory (Li et al., 2016) and antioxidant (Samarghandian et al., 2016 ) effects on rat's brain. Interestingly, the intraperitoneal administration of CA showed a protective effect on the behavioral impairments induced by 6-hydroxydopamine (a hemi-parkinsonism rat model) that was related to an antioxidant action (Baluchnejadmojarad et al., 2014) . Moreover, CA can modulate neurotransmitters systems in CNS, including the dopaminergic system (Zotti et al., 2013) . These results suggest that the natural compound CA has valuable effects on CNS, which could provide protective action against physiopathological alterations of PD.
In this context, the aim of the present study was to investigate the possible protective effect of CA in a RES-induced rat model of Parkinson's disease, with emphasis on behavioral and immunohistochemical effects.
Materials and methods

Animals
Seven-month-old male Wistar rats (n = 46) were used in this study. All animals were housed in groups of four or five per plastic cage (30 cm × 37 cm × 16 cm), under controlled conditions of ventilation, temperature (22 ± 1°C) and a 12/12 h light/dark cycle (lights on 6:00 a.m.), with free access to water and food. Animals used in this study were handled according to the Brazilian law for the use of animals in scientific research (Law number 11.794) and all the procedures were approved by the local Animal Ethics Committee (Protocol number 33/2014). All efforts were made to minimize animal pain, suffering or discomfort and reduce the number of animals used.
Drugs
Carvacrol (5-isopropyl-2-methylphenol, ≥98% purity) and reserpine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Carvacrol (CA) was emulsified with 0.2% Tween 80 and dissolved in saline (0.9% isotonic saline) at the concentrations of 12.5 and 25 mg/ mL. Vehicle of carvacrol (VC) consisted of 0.2% Tween 80 dissolved in saline. Reserpine (RES) was dissolved in glacial acetic acid and then diluted in distilled water at the concentration of 0.1 mg/mL. Vehicle of reserpine (VR) consisted of the same amount of glacial acetic acid diluted in distilled water as in the RES solution. CA and VC were freshly prepared before administration, and RES and VR were prepared every 48 h and kept at 4°C between administrations.
General procedures and experimental design
Before the beginning of experimental procedures, animals were handled daily during five minutes for five consecutive days. Afterwards, the rats were randomly assigned to the following groups: Vehicle of carvacrol + vehicle of reserpine (VC + VR; n = 9); vehicle of carvacrol + reserpine (VC + RES; n = 9); Carvacrol (12.5 mg/kg) + vehicle of reserpine (CA12.5 + VR; n = 7); Carvacrol (25 mg/kg) + vehicle of reserpine (CA25 + VR; n = 7); Carvacrol (12.5 mg/kg) + reserpine (CA12.5 + RES; n = 7) and Carvacrol (25 mg/kg) + reserpine (CA25 + RES; n = 7). The animals received 15 s.c. injections of RES (0.1 mg/kg) or VR every 48 h, and they were concomitantly treated with a daily i.p. injection of CA (12.5 or 25 mg/kg) or VC. The volume of injection was 1 ml/kg of body weight in all cases. The carvacrol injection was given first and reserpine injection was given after a tenminute delay.
Throughout the treatment, the animals were submitted to the following behavioral tests (from 8:00 a.m. to 4:00 p.m.): (1) catalepsy test performed daily; (2) open field test on 7th day (24 h after the 4th injection of RES or VR); (3) assessment of vacuous chewing movements on 12th, 20th and 30th days (48 h after the 6th, 10th and 15th injections of RES or VR, respectively, before the injections). The day of first injection of RES or VR was considered as 0 day. All apparatuses were cleaned with 10% ethanol before behavioral testing to eliminate odor traces. All behavioral tests were conducted before the injections in the respective treatment day. All behavioral analysis were conducted by a trained rater blind to treatment. At the end of the behavioral tests, the animals were transcardially perfused and their brain removed and L.C.R.F. Lins et al. Brain Research Bulletin 139 (2018) 9-15 processed to immunohistochemistry and tyrosine hydroxylase (TH) quantification (Fig. 1) .
Behavioral testing
2.4.1. Catalepsy test Animal's forepaws were placed on a horizontal bar stationed 9 cm above the bench surface. Catalepsy behavior was defined as an immobile posture, when the animal kept steadily both forepaws on the bar. The amount of time the animal remained in the same imposed position was scored until a maximum of 180 s. Three consecutive trials were carried out daily for each animal and the average value of the three trials was considered for analysis (Fernandes et al., 2012; Lins et al., 2017; Santos et al., 2013) .
Open field test
The rats were individually placed in the center of a circular openfield arena (84 cm in diameter and 32 cm high walls) and allowed to freely explore for 10 min. The sessions were recorded by a digital camera fixed above the apparatus and the behavioral parameters were registered using a computerized system for animal tracking (Anymaze, Stoelting Co, Wood Dale, IL, USA). In order to analyze possible changes in the spontaneous locomotor activity caused by treatment, we quantified the total distance traveled (in meters) and number of rearing (Fernandes et al., 2012; Santos et al., 2013) .
Vacuous chewing movements (VCMs)
Rats were individually placed in wire cages (40 cm × 40.5 cm × 20 cm) with mirrors placed underneath and behind the back wall of the cage to enable the behavioral quantification of the oral movements when the animal was facing away from the observer. The number of VCMs (rapid vertical deflection of the lower jaw that resembles chewing, but is not directed at any particular stimulus) was scored continuously for 10 min. If these movements occurred during a period of grooming, they were not taken into account (Fernandes et al., 2012; Peixoto et al., 2005; Salamone et al., 1998) .
Tyrosine hydroxylase (TH) immunohistochemistry
Upon completion of the behavioral tests (48 h after 15th injection of RES or VR), rats (n = 5 per group) were anesthetized with a mixture of Ketamine (100 mg/kg, i.p.) and Xylazine (10 mg/kg, i.p.) and perfused transcardially with 150 ml of 0.1 M phosphate-buffered saline (PBS), pH 7.4, followed by 300 ml of 4% paraformaldehyde (4% PFA) in 0.1 M phosphate buffer (PB), pH 7.4. The brains were quickly removed from the skull and post-fixed overnight in 4% PFA at 4°C. Brains were then placed in 30% sucrose at 4°C for cryoprotection until they sank. Each brain was serially cut in coronal sections of 40 μm using a cryostat microtome (Leica, Germany). The sections were placed sequentially in compartments and stored in antifreeze solution. For the detection of TH, free-floating sections were incubated in blocking solution (2% goat normal serum diluted in 0.3% Triton X-100 and 0.1 M PB, pH 7.4) for 1 h, followed by overnight incubation in monoclonal anti-TH primary antibody diluted in blocking solution (cat # AB152 Chemicon, USA, 1:5000) at room temperature. Afterwards, the sections were incubated with the biotinylated secondary antibody goat anti-rabbit (1:1000; cat# S-1000 Vector Labs, USA) for 2 h at room temperature, washed, and incubated with avidin-biotin-peroxidase solution (ABC Elite kit, Vector Labs, Burlingame, USA) for 90 min. The reaction was developed by the addition of diaminobenzidine tetrahydrochloride (Sigma, USA) and 0.01% H 2 O 2 in 0.1 M PB, pH 7.4. The sections were washed (3 × 5 min) with 0.3% Triton X-100 in 0.1 M PBS (pH 7.4) between each step and at the end of the procedure. Then, the sections were dried, dehydrated in a graded alcohol series, cleared in xylene, and cover slipped with Entellan (Merck). All the immunostainings were performed concomitantly, minimizing possible differences in background between the animals. Sections were examined under bright field illumination (Olympus Microscope, BX-41), images were captured using a CCD camera (Nikon, DXM-1200) and the locations of areas were determined using the Paxinos and Watson rat brain atlas (Paxinos and Watson, 2005) .
Image analysis
In order to estimate the number of dopaminergic cells in the SNpc, four sections of each animal were selected and the number of TH-positive cells was quantified manually using NIH (National Institutes of Health) ImageJ software (Bethesda, MD, USA). Additionally, four representative sections of the dorsal striatum were chosen and TH levels were assessed by analysis of relative optical densitometry (ROD) using the Image J software. In the DOR analysis, the medium pixels in the target area were subtracted from de medium values of a control region (area that should not have specific TH staining) of the same tissue (cortex). Finally, in order to evaluate proportional alterations, all values were normalized considering the average of control group (VC + VR group). All analysis were performed by an investigator blinded to treatment regimen (Santos et al., 2013) .
Statistical analysis
Catalepsy behavior and oral movements were compared between groups across the treatment using repeated measures two-way ANOVA followed by Tukey's test. The open field parameters, number of TH+ cells and ROD data underwent analysis of variance (one way ANOVA) followed by Tukey's test. Results are expressed as mean ± S.E.M. and differences were considered significant when p value was less than 0.05. Additionally, power analyses were conducted for the experiments. We used π ≥ 0.80 as a standard for adequacy. All statistical analyses were performed using Graph Pad Prism 6.0 (Graph Pad Prism Software Inc., San Diego, CA, USA) and PASW ® 18.
Results
Catalepsy test
Repeated-measures two-way ANOVA revealed a significant main effect of time (days of treatment) [F (30, 1200) show any significant difference when compared to control groups. In addition, they showed a significantly lower value of catalepsy duration when compared to VC + RES group, indicating a protective effect (Fig. 2) . (Fig. 3) .
Open field
Vacuous chewing movements (VCMs)
Repeated-measures two-way ANOVA revealed a significant main effect of time (days of treatment) [F (2, 80) = 12.27; p < 0.001; π = 0.986] and treatment [F (5, 40) = 8.25; p < 0.001; π = 0.981] and a significant interaction between factors [F (10, 80) = 2.26; p = 0.019; π = 0.972]. The Tukey's post-hoc test revealed that VC + RES group showed a significant increase in the number of VCMs on 12th (p = 0.002), 20th (p < 0.001) and 30th (p = 0.005) days when compared to the VC + VR group. Interestingly, on 20th day, the number of VCMs in the VC + RES group was significantly higher than CA12.5 + RES (p = 0.001) and CA25 + RES (p < 0.001) groups. In contrast, CA administered concomitantly alone or concomitantly with RES did not induce any significant change in the number of VCMs when compared to the VC + VR group (Fig. 4) .
TH-immunohistochemistry
One way ANOVA showed a significant effect of treatment [F (5, 24) = 9.44; p < 0.001; π = 0.862] on number of TH-positive cells in the SNpc. The Tukey's post hoc test revealed a significant decrease in the number of TH-positive cells in the VC + RES group when compared to control groups [VC + VR (p < 0.001), CA12.5 + VR (p < 0.001) and CA25 + VR (p = 0.012)]. Interestingly, the number of TH-positive cells was significantly higher in the CA12.5 + RES (p < 0.001) and CA25 + RES (p = 0.002) groups when compared to the VC + RES group and they did not differ from the control groups. In addition, CA administered alone did not induce any significant change in the number of TH-positive cells in the SNpc in comparison with VC + VR group (Fig. 5A) .
Regarding the TH levels analyzed by ROD in the dorsal striatum, the one-way ANOVA showed a significant effect of treatment [F (5, 24) = 12.57, p < 0.001; π = 0.819]. The Tukey's post hoc test revealed a significant decrease in the TH levels in the VC + RES group in comparison with control groups [VC + VR (p = 0.009), CA12.5 + VR (p < 0.001) and CA25 + VR (p < 0.001)]. The CA12.5 + RES group also showed a significant decrease in the TH levels when compared to CA12.5 + VR (p = 0.006), CA25 + VR (p < 0.001) and CA25 + RES (p = 0.048) groups, but did not differ from VC + VR group (p = 0.263). Interestingly, the TH levels in the CA25 + RES group were significantly higher when compared to the VC + RES group (p = 0.001) and it did not differ from control groups. In addition, CA administered alone did not induce any significant change in the TH levels in the dorsal striatum when compared to the VC + VR group (Fig. 5B) .
Discussion
In this study, we investigated the possible protective effect of CA in rats submitted to a progressive model of PD induced by repeated administration of a low dose of RES. Our results indicate that CA prevented the catalepsy behavior and vacuous chewing movements induced by RES, but failed to prevent the motor deficits observed in the open field. In addition, CA prevented the reduction of the TH-immunoreactivity in the SNpc and dorsal striatum induced by RES.
RES is an inhibitor of vesicular monoamine transporters 1 and 2 (VMAT-1 and VMAT-2) and reduces monoamine vesicular storage, inducing a marked decrease of the monoamines content in the brain (Bertler, 1961) . This effect results in symptoms and neurochemical alterations in humans (May and Voegele, 1956 ) and animals (Colpaert, 1987; Santos et al., 2013 ) similar to those seen in patients with PD. In experimental animals, RES induces motor alterations, such as catalepsy, hypokinesia, muscle rigidity, tremor, oral dyskinesia and postural flexion (Goldstein et al., 1975; Freitas et al., 2015; Colpaert 1987; Santos et al., 2013; Fernandes et al., 2012) . In this study, we used a Fig. 2 . Effect of CA on duration catalepsy behavior of rats submitted to RES-induced progressive model of PD. Data are expressed as mean ± SEM (n = 7-9 per group). **p < 0.01 and ***p < 0.001 for VC + RES vs.
VC model of PD induced by repeated administration of a low dose (0.1 mg/ kg) of RES in rats. One of the main advantages of such protocol is its ability to induce a gradual appearance of motor impairments, mimicking the progressive nature of PD symptoms, considering that PD is characterized by a progressive onset of motor dysfunction (Fernandes et al., 2012; Santos et al., 2013) . Our results showed that the VC + RES group developed a progressive increase of catalepsy behavior, corroborating previous studies (Fernandes et al., 2012; Santos et al., 2013; Sarmento Silva et al., 2015) that used the same dose of RES (0.1 mg/kg, s.c.). In contrast, CA (12.5 and 25 mg/kg) was able to prevent the catalepsy behavior induced by RES (Fig. 2) . Catalepsy behavior is defined as a failure of the animal to correct an externally imposed posture comparable to the inability of PD patients to initiate movements (Sanberg et al., 1988; Duty and Jenner, 2011) . This behavioral alteration has been related to dysfunctions in some areas involved in the PD pathophysiology, such as striatum and globus pallidus, and it has also been linked to changes in the dopamine levels in the nigrostriatal system (Costall and Naylor, 1974; Sanberg et al., 1988; Santos et al., 2013) . Therefore, the catalepsy test is a useful tool to investigate behavioral and neurochemical alterations related to PD. Catalepsy can be induced by dopamine receptor antagonists, implicating a modulatory role of these receptors in the etiology of this dysfunction (Sanberg et al., 1988; Costall and Naylor, 1974) , and suggesting that dopamine receptor agonists could prevent this behavior. Melo et al. (2011) demonstrated that CA produced an antidepressant-like effect in mice by modulating the activation of both D1 and D2 dopamine receptors. Based on this background, we hypothesized that CA might modulate the activity of dopamine receptors and exert its protective effect on catalepsy test, maybe acting as a dopamine receptor agonist. Indeed, dopamine agonists can antagonize rigidity and hypokinesia induced by RES in rats (Colpaert, 1987) .
Several studies have shown that acute or chronic administration of RES can induce oral movements such as vacuous chewing movements (VCMs) (Neisewander et al., 1994; Abílio et al., 2003; Fernandes et al., 2012) . VCMs share some pharmacological and neurochemical characteristics with parkinsonian resting tremor, suggesting that evaluation of these movements may be used to investigate the efficacy of antiparkinsonian agents (Salamone et al., 1998) . In the present study, we demonstrated that chronic administration of a low dose of RES significantly increased the number of VCMs in the VC + RES group when compared to VC + VR group, starting on day 12. Further, the CA + RES groups did not show any significant difference when compared to control groups, indicating that CA (12.5 and 25 mg/kg) was able to attenuate the VCMs induced by RES. In addition, those groups showed a lower number of VCMs induced by RES on day 20, when the RES effect was more prominent (Fig. 4) . A GABAergic hypofunction in the basal Fig. 4 . Effect of CA on number of vacuous chewing movements of rats submitted to RES-induced progressive model of PD. Data are expressed as mean ± SEM (n = 7-9 per group). **p < 0.01 and ***p < 0. ganglia has been associated with pathophysiology of RES-induced oral movements. In this respect, GABAergic agonists can inhibit these movements (Obeso et al., 2008; Finn et al., 1997; Peixoto et al., 2005) . Some studies have suggested that CA has effects on GABAergic neurotransmission, including a modulator effect on GABA A receptors. CA showed a potentiating effect on GABA-evoked currents in inject Xenopus oocytes and transfected HEK293 cells expressing rat GABA A receptors (Kessler et al., 2014) . Melo et al. (2010) showed that the anxiolytic effect of CA was reversed by flumazenil pretreatment, a recognized antagonist of the benzodiazepine site in the GABA A -receptor. In addition, CA was able to protect mice against pentylenetetrazol-induced convulsions. This convulsant agent is a noncompetitive antagonist of the GABA A -receptor (Quintans-júnior et al., 2010) . Although the mechanisms involved with the protective effect of CA against RES-induced VCMs are still unclear, it is possible that CA effect can be related with its modulatory activity on GABAergic system. It has been suggested that the oral movements induced by neuroleptic treatment in rats can be caused by a reduction in spontaneous motor activity (Andreassen and Jorgensen, 2000) . Thus, a reduction of locomotor activity induced by RES could influence the development of VCMs. In this respect, we observed that RES-treated rats showed a significant reduction in the spontaneous motor activity in the open field test, and CA failed to reverse this effect (Fig. 3 ). Nevertheless, CA was able to prevent the oral movements induced by RES (Fig. 4) . Thus, our results indicate that the reduction of spontaneous motor activity induced by RES did not influence the protective effect of CA on RESinduced VCMs, suggesting that different mechanisms may be involved in mediating these effects of CA. Indeed, VCMs induced by RES can be observed in different motor conditions and some studies indicate that reduction of motor activity is not related to the development of oral movements, suggesting that these behavioral manifestations caused by RES are regulated by distinct pathophysiological mechanisms (Faria et al., 2005; Fernandes et al., 2012; Peres et al., 2016) .
As mentioned bellow, the greatest effect of CA was observed on day 20 when the VCM was evaluated. This outcome raises the question that CA may not have long lasting benefits. Of notice, however, the effects of CA treatment endured until the end of treatment when the catalepsy data were considered. Also, it is possible the effect observed on day 30 of VCM evaluation is not associated to reduction of beneficial of CA treatment, or that CA + RES groups are showing more VCM scores from day 20, but it is rather that the RES group is showing reduced VCM scores on day 30 compared to day 20, which could explain the absence of statistical difference observed on day 20 between CA + RES groups and VC + RES group. Thus, we can suggest the carvacrol demonstrated lasting behavioral benefits, at least under our experimental conditions. Nevertheless, the duration of the effects of CA treatment is an important issue because we do not know if carvacrol effects would hold with longer treatments, especially considering that in the human condition Parkinson's disease would continue to progress. This issue remains for future investigations.
A large body of literature has demonstrated that RES-induced oral movements are closely related to oxidative stress (Calvente et al., 2002; Abílio et al., 2004; Fernandes et al., 2012; Leão et al., 2015) and antioxidant agents can attenuate or inhibit these movements (Abílio et al., 2003; Burger et al., 2003; Faria et al., 2005) . Although we did not evaluate the antioxidant effect of CA in the present study, we hypothesize that the protective effect of CA on RES-induced oral movements may also be associated with its antioxidant activity. Indeed, previous in vitro (Guimarães et al., 2010; Aazza et al., 2011; Coccimiglio et al., 2016; ) and in vivo studies (Celik et al., 2013; Baluchnejadmojarad et al., 2014; Samarghandian et al., 2016) have reported that CA has strong antioxidant properties.
Accordinly, RES has been reported to induce oxidative stress in rodent brain (Abílio et al., 2003; Burger et al., 2003; Fernandes et al., 2012; Spina and Cohen, 1989) , resulting in neuronal damage and decrease of TH expression in the SNpc and dorsal striatum (Santos et al., 2013; Leão et al., 2015) . Moreover, it has been suggested that oxidative stress plays an important role in generation of cellular dysfunction and demise in PD (Hwang, 2013) . Thus, RES-induced parkinosism has been used in the screening of antioxidant and neuroprotective agents for potential treatment of PD (Leão et al., 2015; Sarmento Silva et al., 2015; Peres et al., 2016) . In the present study, we observed a significant reduction in the number of TH-positive cells in the SNpc (Fig. 5A ) and in the ROD values for TH in the dorsal striatum (Fig. 5B) in the rats of the VC + RES group, but no such reduction was observed in the CA-treated groups when compared to the VC + VR group. It should be noted that only the CA25 + RES group showed a significant difference when compared to VC + RES group in both areas, suggesting that CA had a neuroprotective effect, and the highest CA dose seems to produce better results. The enzyme TH is responsible for a critical step in the synthesis of dopamine and has been used as an indirect evidence to estimate levels of dopamine in the brain of rodents (Santos et al., 2013) . We can hypothesize that CA could easily cross the blood-brain barrier, taken up by neurons and prevent the oxidative stress caused by RES, acting as a neuroprotective agent to dopaminergic neurons, but this remains to be investigated.
In summary, our preliminary data suggest that CA exerts protective effect in a progressive model of PD induced by RES. However, the limitations of the current study should be considered, since we did not perform any protocol to evaluate the mechanism of action involved with the potential protective effect of CA. Thus, additional studies must be carried out to systematically evaluate the specific effect of CA on behavioral and neurochemical alterations induced by RES. A further understanding of how CA exerts beneficial effects in this model may have profound implications for the prevention or treatment of PD.
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